| Calcium Channel Blocker in Myotonic Dystrophy Type 1 (NCT07075965) | University of Rochester | 2026-12-07 |
| Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma (NCT07422363) | National Cancer Institute (NCI) | 2026-12-04 |
| XVIE to Treat Androgenetic Alopecia (AGA) (NCT07482423) | Restore Biologics Holdings, Inc. dba Xtressé | 2026-12-01 |
| Personalized Antisense Oligonucleotide Therapy for a Participant With TARDBP ALS (NCT07703462) | n-Lorem Foundation | 2026-12-01 |
| A Phase I Evaluation of the Safety and Tolerability of Pirfenidone in Idiopathic Subglottic Stenosis (NCT07654517) | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 2026-12-01 |
| Use of ACU-D1 in HPV Associated Vulvar and Perianal Lesions in People With HIV (NCT06233331) | Emory University | 2026-12-01 |
| Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma (NCT07600151) | Universitätsklinikum Hamburg-Eppendorf | 2026-12-01 |
| Minocycline In Neurocognitive Outcomes - Sickle Cell Disease (NCT05605366) | University of Cincinnati | 2026-12-01 |
| ZR001 Chemogenetics Gene Therapy Study in Patients With Parkinson's Disease (NCT07718659) | Qianfoshan Hospital | 2026-12-01 |
| A Study to Evaluate the Safety and Antiviral Activity of Two Human Monoclonal Antibodies (VRC07-523LS and PGT121.414.LS) During Analytic Treatment Interruption in Participants Living With HIV Who Initiated ART During Acute/Early HIV-1 Infection (NCT06987318) | National Institute of Allergy and Infectious Diseases (NIAID) | 2026-12-01 |
| Evaluate the Safety and Tolerability of CE211NS21 in Patients With AQP4-IgG-positive NMOSD Relapse (NCT07595965) | Corestemchemon, Inc. | 2026-12-01 |
| Targeted LSAM-Cisplatin Infusion in Gliomas, Evaluation of Response (NCT07767110) | NanOlogy, LLC | 2026-12-01 |
| Longitudinal PET Imaging of Antipsychotic Binding to the Dopamine-3 Receptor in Schizophrenia (NCT07715253) | New York State Psychiatric Institute | 2026-12-01 |
| The Effect of Inhaled Nitric Oxide on Pulmonary Gas-exchange in COPD (NCT04231760) | University of Alberta | 2026-12-01 |
| Revumenib in Patients With Myelofibrosis (NCT07734077) | John Mascarenhas | 2026-12-01 |
| A Phase 1b/2a Study of Velinotamig in Adults With Relapsed/Refractory ITP and wAIHA (NCT07738822) | Cullinan Therapeutics Inc. | 2026-12-01 |
| Mercaptopurine for the Treatment of Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC), Uterine/Cutaneous Leiomyomas, and Kidney Cancer (NCT07716735) | Jonsson Comprehensive Cancer Center | 2026-12-01 |
| BC-101 in Treatment of Nasolabial Fold Wrinkles (NCT05162326) | Bright Cell, Inc. | 2026-12-01 |
| Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer (NCT07667335) | Fred Hutchinson Cancer Center | 2026-12-01 |
| A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation (NCT07752875) | LG Chem | 2026-12-01 |
| Psilocybin Effects on Healthy Aging Biomarkers and Purpose in Life (NCT07719088) | Charles Raison | 2026-12-01 |
| Effects of Sirolimus on Asymptomatic ApoE4 Carriers (NCT07728175) | University of Missouri-Columbia | 2026-12-01 |
| Study to Compare Blood Levels of Ceftriaxone Given by Suppository or Injection. (NCT03895567) | University of Oxford | 2026-12-01 |
| Safety Study of Intravenous MiraMSC in Older Adults With Mild to Moderate Frailty Syndrome (NCT07705464) | Miracle Biomedical Co., Ltd. | 2026-12-01 |
| OLIG2 Inhibitor CT-179 for Recurrent and Newly-diagnosed Glioblastoma (NCT07739017) | Olivia Newton-John Cancer Research Institute | 2026-12-01 |
| CD30 CAR T-cells Post AutoHSCT for Poor-risk Hodgkin Lymphoma (NCT06617286) | New York Medical College | 2026-12-01 |
| Safety and Tolerability of a Single Intravenous Infusion of BX-U001 in Refractory Rheumatoid Arthritis (NCT03828344) | Baylx Inc. | 2026-12-01 |
| 3-Dimensional Virtual Reality Modelling With Intravascular Indocyanine Green Fluorescence Mapping for Targeted Pulmonary Segmental Resection Trial (NCT06638125) | St. Joseph's Healthcare Hamilton | 2026-12-01 |
| Study Examining the Safety and Toxicity of Stereotactic Body Radiotherapy (SBRT) Followed by PCX12 Immunotherapy Delivered by Intratumoral Injection for the Treatment of Patients With Locally Advanced Pancreatic Adenocarcinoma (LAPC) (NCT06217666) | Haoming (Carl) Qiu | 2026-12-01 |
| PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP (PRISM-TAMP) (NCT07477418) | University of Vermont | 2026-12-01 |
| Evaluating AVM0703 for Treatment of COVID-19 or Influenza-mediated ARDS (NCT04366115) | AVM Biotechnology Inc | 2026-12-01 |
| Study to Investigate the Safety of the Transplantation (by Injection) of Human Glial Restricted Progenitor Cells (hGRPs; Q-Cells®) Into Subjects With Amyotrophic Lateral Sclerosis (ALS) (NCT02478450) | Q Therapeutics, Inc. | 2026-12-01 |
| Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML (NCT07604233) | M.D. Anderson Cancer Center | 2026-11-30 |
| Sipuleucel-T (Sip-T) in Combination With N-803 in Metastatic Androgen Pathway Modulation Resistant (mAPMR) Prostate Cancer (NCT07756593) | Washington University School of Medicine | 2026-11-30 |
| Ph1/2 Trial Of Navlimetostat With Pumitamig In MTAP-Deficient Advanced Non-Small Cell Lung Cancer (NCT07579221) | M.D. Anderson Cancer Center | 2026-11-30 |
| A Phase 1b/2 Study of Ropeginterferon Alfa-2b Added to Azacitidine in Newly Diagnosed MDS/AML (≥ 10% Blasts) With TP53 Mutations (NCT07646821) | M.D. Anderson Cancer Center | 2026-11-27 |
| A Study of Subcutaneously Administered RO7845860 in Participants With Relapsing Multiple Sclerosis (NCT07749157) | Hoffmann-La Roche | 2026-11-23 |
| A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia (NCT07283640) | M.D. Anderson Cancer Center | 2026-11-18 |
| A Study Evaluating the Safety, Tolerability, and Activity of ICM-203 in Subjects With Knee Osteoarthritis. (NCT05454566) | ICM Co. Ltd. | 2026-11-15 |
| Y-NM600 in Patients Receiving Anti-PD-1 or Anti-PD-L1 for Metastatic Cancer (NCT07197671) | University of Wisconsin, Madison | 2026-11-01 |
| Feasibility and Acceptability of Amani (NCT07648043) | Massachusetts General Hospital | 2026-11-01 |
| A Clinical Study of Piperaquine, Pyronaridine, and Artesunate Administered in Combination in Healthy Adults (NCT07470424) | University of Oxford | 2026-11-01 |
| Autologous Tumor Infiltrating Lymphocyte (TIL) GT201 Infusion. (NCT07766317) | Gritbio Medicine, Inc. | 2026-11-01 |
| First In Human Randomised Trial of Rincell-1 in Adults With a Cochlear Implant (NCT07032038) | Rinri Therapeutics | 2026-11-01 |
| Gene-edited T Regulatory Cells (CRG-150) for the Treatment of Relapsed/Refractory Malignancies (NCT07730125) | CoRegen, Inc. | 2026-11-01 |
| Arsenic Trioxide to Prevent Relapse in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia or Myelodysplastic Syndrome (NCT07737769) | University of Michigan Rogel Cancer Center | 2026-11-01 |
| EBV-Tscm Cytotoxic T Cells (CTLs) for EBV- Driven Lymphomas/ Diseases (NCT05688241) | University Hospital, Basel, Switzerland | 2026-11-01 |
| Enhancing Wound Perfusion in High-Risk Lower Extremity Orthopaedic Surgery: A Study on Nitropaste Using Intraoperative SPY Imaging. (NCT07004764) | Johns Hopkins University | 2026-11-01 |
| Pilot Testing of Vagus Nerve Stimulation for Early Spinal Cord Injury Recovery (NCT07562113) | University of Alabama at Birmingham | 2026-11-01 |
| CD19/CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relapsed/Refractory B-cell Malignancies (NCT07763938) | The First Affiliated Hospital with Nanjing Medical University | 2026-11-01 |
| IKS04 Regimen in Advanced Solid Tumors That Express CA242 (NCT07738939) | Iksuda Therapeutics Ltd. | 2026-11-01 |
| Study of the Safety and Efficacy of Pancreatic Endocrine Cells in Adult Patients With Type 1 Diabetes (NCT07581197) | Seraxis | 2026-11-01 |
| Study Evaluating the Safety Feasibility and Efficacy of ODI-2001 Vaccine, a Personnalized Immunotherapy in Patients With Metastatic or Locally Advanced Colon Cancer or Pancreatic Cancer (NCT07587827) | Centre Georges Francois Leclerc | 2026-11-01 |
| Chimeric Receptor T Cells With Trastuzumab in HER2+ Advanced Breast Cancer and Other Solid Tumors (NCT06027983) | National University Hospital, Singapore | 2026-11-01 |
| Oral Dexmedetomidine in Pediatric MRI (NCT05619627) | Soroush Merchant | 2026-11-01 |
| Anakinra Rescue Treatment for Moderate Asthma Attacks (ARTMA) (NCT07600190) | University of North Carolina, Chapel Hill | 2026-11-01 |
| S-Adenosylmethionine (SAMe) for Chemoprevention of Colorectal Adenomas (NCT07582003) | Jun Gong, MD | 2026-11-01 |
| A Novel Proline-rich Peptide Hydrogel for Periodontal Regeneration in Adult Periodontitis Patients (NCT07581613) | Siddharth Shanbhag | 2026-11-01 |
| Axelopran and Nivolumab in PD-1-Refractory Metastatic Melanoma (NCT07631325) | John Kirkwood | 2026-10-31 |
| Axatilimab + CAR-T for High-Risk Lymphoma (NCT07638982) | Northside Hospital, Inc. | 2026-10-31 |
| Prophylactic and Therapeutic DLI-X for Leukemia Relapse After HCT (NCT07254793) | University of Arizona | 2026-10-31 |
| A Study to Assess Sulbactam-durlobactam in Pediatric Patients With Acinetobacter Baumannii-calcoaceticus Complex Infection (NCT06801223) | Innoviva Specialty Therapeutics | 2026-10-30 |
| Clinical Study on Drug Interactions of Flonoltinib Maleate Tablets (NCT07768111) | Chengdu Zenitar Biomedical Technology Co., Ltd | 2026-10-30 |
| A Phase 1, Multicenter Imaging Study of LNTH-2403 in Participants With Locally Advanced or Metastatic Solid Tumors. (NCT07272642) | Radiopharm Theranostics, Ltd | 2026-10-30 |
| Pharmacokinetics Study of Larotinib in Subjects With Impaired Hepatic Function (NCT05048368) | Sunshine Lake Pharma Co., Ltd. | 2026-10-30 |
| A Seamless, Adaptive Multiple-Ascending-Dose and Efficacy Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extrapulmonary Manifestations (NCT07680166) | Xentria, Inc. | 2026-10-30 |
| Study to Characterise Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Anifrolumab Administered Subcutaneously (SC) or Intravenously (IV) (NCT07688980) | AstraZeneca | 2026-10-30 |
| Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse (NCT07437963) | National Cancer Institute (NCI) | 2026-10-28 |
| A Study in Healthy Male Participants to Compare How CHF10196 Affects How the Body Absorbs and Processes Two Commonly Used Medicines: Dabigatran, a Blood Thinner, and Rosuvastatin, a Medicine Used to Lower Cholesterol (NCT07744386) | Chiesi Farmaceutici S.p.A. | 2026-10-27 |
| ABBV-383 for the Treatment of Relapsed Refractory Waldenström Macroglobulinemia (NCT07420959) | Mayo Clinic | 2026-10-25 |
| A Phase1 Clinical Trial Evaluating Locoregional Delivery Of Engineered NK Cells Containing IL13Ra And EGFvIII Chimeric Antigen Receptor (CAR), IL-21 Secretion And Deleted TGF-BetaR2 And NR3C1 In Recurrent Glioblastoma (NCT07579208) | M.D. Anderson Cancer Center | 2026-10-24 |
| A Study of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Multiple Myeloma and Moderate Hepatic Impairment (NCT07609706) | GlaxoSmithKline | 2026-10-23 |
| hiPSC-CMs-loaded Chitosan Patch to Treat Severe Chronic Ischemic Heart Disease (NCT07471698) | HELP Therapeutics Co., Ltd. | 2026-10-20 |
| A Phase 1b, Open-Label Study Of REC-617, A Selective CDK7 Inhibitor, In Patients With Metastatic Or Unresectable RB1-Negative Leiomyosarcoma After Prior Systemic Therapy (NCT07633756) | M.D. Anderson Cancer Center | 2026-10-19 |
| A Study to Evaluate the Subcutaneous Belantamab (BCMAb) Formulation Versus Intravenous Belantamab in Participants With Multiple Myeloma While Treated With Standard of Care (NCT07742527) | GlaxoSmithKline | 2026-10-16 |
| A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML Patients (NCT07722767) | Cullinan Therapeutics Inc. | 2026-10-15 |
| A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2511 in Participants With Early Alzheimer's Disease (AD) (NCT07768592) | Eisai Inc. | 2026-10-15 |
| A Study to Compare How CHF10196 (Florensocatib) is Absorbed Into the Blood When Given Alone and With a Drug That Reduces Stomach Acid in Healthy Male Participants (NCT07683793) | Chiesi Farmaceutici S.p.A. | 2026-10-14 |
| AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study") (NCT07649304) | National Cancer Institute (NCI) | 2026-10-09 |
| Food Effect and Multiple-Dose Study of Chiglitazar/Metformin Extended-Release Tablets (NCT07511010) | Chipscreen Biosciences, Ltd. | 2026-10-08 |
| Trial of NLG802 Indoximod Prodrug Plus Temozolomide for Patients With Progressive Pediatric Brain Cancer (NCT07732413) | Lumos Pharma | 2026-10-08 |
| Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer (NCT07137416) | National Cancer Institute (NCI) | 2026-10-05 |
| LUT017 Gel for Venous Leg Ulcers and Chronic Non-Healing Skin Wounds in Adults (NCT07463365) | Antoni Ribas | 2026-10-02 |
| Psilocybin for Chronic Pelvic Pain (CPP) in Women: A Pilot Feasibility Study (NCT06988319) | Oregon Health and Science University | 2026-10-01 |
| Allogeneic iNKT Cell Therapy (agenT-797) After SCT (NCT07758218) | University of Wisconsin, Madison | 2026-10-01 |
| Phase I Study Of PLM-102 In Patients With Relapsed And Refractory Acute Myeloid Leukemia (NCT07549464) | M.D. Anderson Cancer Center | 2026-10-01 |
| Study of Neoadjuvant RBP-01 In Patients With Primary Uveal Melanoma (NCT07747935) | ReBio Pharma | 2026-10-01 |
| Bispecific CD19/CD20-Targeted Chimeric Antigen Receptor (CAR) Modified T Cells With 4-1BB and Mutated CD28 Costimulatory Domains in Patients With Relapsed or Refractory CD19+ Hematologic Malignancies (NCT07701889) | Roswell Park Cancer Institute | 2026-10-01 |
| Oral Zn-Telomir Monotherapy in Patients With Advanced or Metastatic Triple-Negative Breast Cancer (TNBC) (NCT07581314) | Telomir Pharmaceuticals, Inc. | 2026-10-01 |
| A Phase 1 Study of UB-VV500 With Rapamycin in Relapsed/Refractory Multiple Myeloma (NCT07735546) | Umoja Biopharma | 2026-10-01 |
| Study of TUB-040 in Patients With Recurrent or Progressive Uterine Cancer After Chemotherapy and Immune Therapy (NCT07743541) | Tubulis GmbH | 2026-10-01 |
| NANOVAE to Treat Knee Osteoarthritis (KOA) (NCT06606561) | Nova Vita Laboratory | 2026-10-01 |
| EWSR1 Immunotherapy in Ewing Sarcoma and DSRCT (NCT07695311) | Rabi Hanna | 2026-10-01 |
| A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia (NCT07770698) | BeOne Medicines | 2026-10-01 |
| AI-DBT For Serious Illness (NCT07748312) | Rutgers, The State University of New Jersey | 2026-10-01 |
| Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectable, or Locally Advanced Basal Pancreatic Cancer (NCT07645651) | University of Washington | 2026-10-01 |
| A Study of LP-118 In Combination With Ponatinib, Dexamethasone And Blinatumomab For Adults With Newly-Diagnosed, BCR::ABL1-Positive Acute Lymphoblastic Leukemia (ALL) (NCT07614022) | Wake Forest University Health Sciences | 2026-10-01 |
| Study to Evaluate Safety and Activity of Inhaled TRL1068 in Healthy Volunteers (NCT07644195) | Trellis Bioscience LLC | 2026-10-01 |
| Enhancing Rehabilitation in Aging Study (ERAS) (NCT07704385) | University of Florida | 2026-10-01 |
| Examining the Role of Tolerance on Dose-dependent Effects of Acute THC on Oculomotor and Cognitive Performance (NCT06351540) | Johns Hopkins University | 2026-10-01 |